Uncertainty About Supply Chain Keeps Baxter Out Of Heparin Market
This article was originally published in PharmAsia News
Executive Summary
Baxter International is unsure whether it will re-enter the prescription blood thinner heparin market due in part to concerns about a "complex and difficult" ingredient supply chain, according to CEO Robert Parkinson.
You may also be interested in...
U.S. FDA Triples Estimate On Deaths Following Allergic Reaction To Blood Thinner Heparin
BEIJING - U.S. FDA last week issued a sharply higher estimate on the number of deaths that have occurred in patients who suffered allergic reactions to the blood thinner heparin
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).